Torigen Pharmaceutical, a Farmington, CT-based commercial-stage animal health biologics company, raised $13M Series A1 funding.
The round was led by Werth Family Investment Associates, and Connecticut Innovations, with participation from Emerald Development Managers, Gaingels, Kema Fund, University of Notre Dame, SoGal Ventures, UCONN Innovation Fund, Ironwood Capital and Advantage Capital.
The company intends to use the funds to continue to develop new products and expand its salesforce.
Led by CEO Ashley Kalinauskas, Torigen aims to innovate pet cancer treatment by leveraging the pet’s immune system to create personalized cancer immunotherapies. It is a spin-out from the University of Notre Dame.